Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
Cancers|February 12, 2021
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate CancerTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancer Science|September 27, 2023
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumabKazumasa Komura, Satoshi Tokushige, Mitsuaki Ishida, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
The Journal of Clinical Investigation|June 5, 2018
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5DKazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Cancers|November 26, 2022
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Takaya Ohno, Kazumasa Komura, et al.
Cancer Medicine|September 14, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancerTakuya Tsujino, Satoshi Tokushige, Kazumasa Komura, et al.
Pageof 19